{"filings":[{"id":1949717,"accession_number":"0000872589-26-000023","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2026-07-30T10:48:32+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q2 2026 revenue up 17% to $4.3B; non-GAAP EPS $14.29 beats; Dupixent sales up 38%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $4.291B (+17% YoY); GAAP EPS $12.23 (incl. $1.02 IPR&D charge); non-GAAP EPS $14.29 (+11%).","Dupixent global net sales (Sanofi) up 38% to $6.0B; EYLEA HD U.S. net sales up 52% to $596M; Libtayo global up 30% to $489M.","Sanofi Development Balance fully repaid; collaboration profits to step up in Q3. Guidance raised: GAAP gross margin 78-79% (prior 77-78%).","Cemdisiran NDA accepted for gMG with priority review; FDA target action date Nov 2026.","Share repurchases $1.2B in Q2; $2.0B in H1; dividend $0.94/share declared."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1453438,"accession_number":"0001104659-26-080562","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2026-07-06T11:00:40+00:00","items":["2.02"],"status":"ready","headline":"Regeneron expects ~$127M IPR&D charge in Q2 2026, reducing EPS by ~$1.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pre-tax acquired IPR&D charge of ~$127M from collaboration and licensing up-front/opt-in payments.","Charge expected to reduce both GAAP and non-GAAP diluted EPS by ~$1.00 in Q2 2026.","Q2 2026 results not finalized; subject to financial statement closing procedures.","Company does not forecast such IPR&D charges due to uncertainty of timing and magnitude."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1111040,"accession_number":"0001104659-26-075127","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2026-06-17T20:05:37+00:00","items":["5.07"],"status":"ready","headline":"Regeneron shareholders elect Class II directors, approve auditor and advisory compensation at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five Class II director nominees elected: Goldstein, Poon, Schenkein, Thompson, Zoghbi.","Ratification of PwC as independent auditor for FY 2026: 102.5M for, 6.4M against, 68.8K abstain.","Advisory vote on executive compensation approved: 96.5M for, 6.9M against, 105.5K abstain, 5.5M broker non-votes.","Meeting held June 12, 2026; results reported June 17, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99307,"accession_number":"0000872589-26-000014","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q1 revenue up 19% to $3.6B; non-GAAP EPS $9.47; gross margin guidance cut","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $3,605M (+19% YoY); GAAP EPS $6.75, non-GAAP EPS $9.47.","EYLEA HD U.S. net sales $468M (+52%); EYLEA HD+EYLEA total U.S. down 10% to $941M.","Dupixent global net sales (Sanofi) up 33% to $4.9B; new approvals for CSU in children and AFRS.","New $3.0B share repurchase authorized; $803M bought back in Q1; dividend $0.94/share.","FY2026 GAAP gross margin guidance reduced to 77%-78% from 79%-80% due to Limerick plant disruption."],"consensus_eps_estimate":null,"consensus_eps_actual":6.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":3605400000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99306,"accession_number":"0001104659-26-040661","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2026-04-08T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Regeneron expects ~$102M IPR&D charge in Q1 2026, ~$0.81 EPS hit","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Pre-tax acquired IPR&D charge of ~$102M from milestone/up-front payments and equity securities premium.","Charge expected to reduce GAAP and non-GAAP diluted EPS by ~$0.81 each for Q1 2026.","Results are preliminary, subject to closing procedures; actuals may differ.","Regeneron does not forecast such charges due to transaction uncertainty.","Company reiterates non-GAAP measure excludes certain items not viewed as useful."],"consensus_eps_estimate":null,"consensus_eps_actual":6.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":3605400000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115224,"accession_number":"0000872589-26-000004","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q4 rev $3.88B (+3%), GAAP EPS $7.86; Dupixent +34% to $4.9B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 total revenue $3.884B (+3% YoY); GAAP diluted EPS $7.86 (vs $8.06 Q4 2024); non-GAAP EPS $11.44 (vs $12.07).","Dupixent global net sales (Sanofi) $4.9B in Q4, +34% YoY; full year $17.8B +26%.","EYLEA HD U.S. net sales $506M (+66%) but total EYLEA franchise fell 28% to $1.1B on competition and patient transition.","FDA approved EYLEA HD for RVO and monthly dosing; new vial filler approved; Libtayo approved as first immunotherapy for adjuvant CSCC.","2026 guidance: GAAP R&D $6.45-6.68B, non-GAAP gross margin 83-84%; quarterly dividend raised to $0.94/share."],"consensus_eps_estimate":null,"consensus_eps_actual":41.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":14342900000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115223,"accession_number":"0001104659-26-002691","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Regeneron expects Q4 IPR&D charge of ~$19M and $60M matching donation charge","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expects ~$19M pre-tax IPR&D charge in Q4 2025, reducing GAAP and non-GAAP diluted EPS by ~$0.14.","Records ~$60M SG&A charge for matching donations to Good Days retinal fund in Q4 2025.","Preliminary Q4 and FY2025 financial update provided at J.P. Morgan Healthcare Conference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131644,"accession_number":"0000872589-25-000026","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q3'25: Revenue $3.75B (+1%), GAAP EPS $13.62, Non-GAAP EPS $11.83; EYLEA sales down 28%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $3.754B (+1% YoY); GAAP EPS $13.62 (+18%), non-GAAP EPS $11.83 (-5%).","Dupixent global net sales (Sanofi) up 27% to $4.86B; total EYLEA HD+EYLEA U.S. down 28% to $1.11B.","FDA approved Libtayo for adjuvant CSCC; positive Phase 3 data for cemdisiran in myasthenia gravis and DB-OTO gene therapy in hearing loss.","2025 guidance revised: GAAP R&D $5.68-5.75B, GAAP SG&A $2.775-2.845B, gross margin about 82%, ETR about 14%."],"consensus_eps_estimate":null,"consensus_eps_actual":33.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":10458600000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131643,"accession_number":"0001104659-25-096921","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Regeneron expects Q3 2025 pre-tax IPR&D charge of ~$83M, reducing EPS by $0.68","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pre-tax acquired IPR&D charge of ~$83M for Q3 2025, primarily from $80M upfront to Hansoh Pharma.","Charge expected to reduce GAAP and non-GAAP diluted EPS by approximately $0.68 per share.","Preliminary results subject to financial statement closing procedures and may change.","Regeneron does not forecast such IPR&D charges due to uncertainty in timing and magnitude."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148210,"accession_number":"0000872589-25-000017","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q2 revenue $3.68B (+4%), GAAP EPS $12.81, non-GAAP EPS $12.89; Dupixent sales +22%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.676B (+4% YoY); GAAP net income $1.392B, GAAP EPS $12.81 (+3%); non-GAAP EPS $12.89 (+12%).","Dupixent global net sales (Sanofi) up 22% to $4.34B; EYLEA HD U.S. net sales up 29% to $393M, total EYLEA U.S. down 25% to $1.15B.","FDA approved Lynozyfic (linvoseltamab) for relapsed/refractory multiple myeloma and Dupixent for bullous pemphigoid and chronic spontaneous urticaria.","EYLEA HD PDUFA delayed due to FDA filler inspection; odronextamab received CRL; company expects expeditious resolution.","In-licensed late-stage dual GLP-1/GIP agonist from Hansoh; Q2 share repurchases $1.07B; $0.88 dividend declared."],"consensus_eps_estimate":null,"consensus_eps_actual":20.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":6704300000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166980,"accession_number":"0001104659-25-060637","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Regeneron shareholders elect directors, approve board declassification; two supermajority amendments fail","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class I directors elected: Bassler (87.3M for, 18.6M against), Brown (77.0M for, 28.9M against), Schleifer (99.3M for), Yancopoulos (101.4M for).","Board declassification amendment approved (85.7M for, 20.2M against, 5.6M broker non-votes).","Proposal to amend Class A stock conversion supermajority vote failed (0 Class A for, 18.1M against).","Proposal to remove 80% supermajority for director removal also failed (85.5M for, 20.4M against, not meeting required vote).","Advisory vote on executive compensation approved (98.8M for, 7.1M against); auditor ratification also passed (105.5M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166979,"accession_number":"0001804220-25-000020","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q1 revenue down 4%, non-GAAP EPS falls 14%; lowers gross margin guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 revenue $3.03B (-4% YoY); GAAP EPS $7.27 (+16%), non-GAAP EPS $8.22 (-14%).","Dupixent global net sales (Sanofi) up 19% to $3.67B; EYLEA HD US up 54% but total EYLEA franchise down 26% to $1.04B.","FDA issued CRL for EYLEA HD pre-filled syringe (non-safety, third-party supplier issue) and separate CRL denying extended dosing beyond every 16 weeks.","Lowers 2025 GAAP gross margin guidance to 83%-84%, non-GAAP to 86%-87% (prior 84%-85% and 87%-88%).","Settled EYLEA biosimilar litigation with Biocon; launch precluded until H2 2026; entered 10-year manufacturing agreement with Fujifilm."],"consensus_eps_estimate":null,"consensus_eps_actual":7.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":3028700000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184363,"accession_number":"0001804220-25-000007","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Regeneron Q4 revenue up 10% to $3.79B; initiates $0.88 quarterly dividend, adds $3B buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP diluted EPS $8.06 (-21% YoY); non-GAAP diluted EPS $12.07 (+2% YoY). Full year revenue $14.20B (+8%).","Q4 Dupixent global net sales $3.70B (+15%); EYLEA HD/EYLEA US net sales $1.50B (+2%); Libtayo global $367M (+50%).","Initiated quarterly cash dividend of $0.88/share, payable March 20, 2025. Board authorized additional $3.0B share repurchase (total capacity ~$4.5B).","Regulatory applications submitted for EYLEA HD pre-filled syringe, Dupixent in bullous pemphigoid, linvoseltamab, and odronextamab."],"consensus_eps_estimate":null,"consensus_eps_actual":38.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":14202000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184362,"accession_number":"0001104659-25-002826","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Regeneron reports 2024 prelim EYLEA sales $6B; Libtayo >$1B; Dupixent >1M patients; pipeline updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["EYLEA HD and EYLEA aggregate U.S. net sales $6B for 2024 (+1% YoY); Q4 combined $1.5B (EYLEA HD $305M).","Libtayo exceeded $1B in 2024 annual net sales; Phase 3 adjuvant CSCC shows 68% risk reduction vs placebo.","New Truveta collaboration to sequence up to 10M additional individuals; RGC has sequenced ~3M people.","Preliminary Q4 2024 IPR&D charge ~$14M pre-tax, expected to impact GAAP and non-GAAP EPS by ~$0.11.","Dupixent now used by over 1M patients globally; linvoseltamab BLA resubmitted with launch anticipated mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":38.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":14202000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200955,"accession_number":"0001804220-24-000038","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q3 revenue up 11% to $3.72B; GAAP EPS $11.54; Dupixent sales +23%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.72B (+11% YoY); GAAP net income $1.34B, diluted EPS $11.54 (up 30%).","Non-GAAP diluted EPS $12.46 (up 8%); includes $0.43 unfavorable IPR&D charge.","Dupixent global net sales $3.82B (+23%, recorded by Sanofi); EYLEA HD+EYLEA US $1.54B (+3%).","FDA approved Dupixent for COPD in Sept. 2024; positive Phase 3 data for CSU and bullous pemphigoid.","FY 2024 guidance updated: GAAP R&D $5.055-5.145B, SG&A $2.93-3.02B; share repurchases $738M in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":30.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":10412800000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200954,"accession_number":"0001104659-24-106432","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Regeneron expects $56M pre-tax IPR&D charge in Q3 2024, reducing EPS by $0.43","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary $56M pre-tax acquired IPR&D charge expected for Q3 2024 from milestone/up-front payments.","GAAP and non-GAAP diluted EPS expected to be negatively impacted by approximately $0.43.","Charge relates to collaboration and licensing agreement payments; such charges are not forecast.","Q3 2024 financial results are not finalized and subject to closing procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216968,"accession_number":"0001804220-24-000026","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q2 revenue up 12% to $3.55B, EPS beats; EU approves Dupixent for COPD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $3.55B (+12% YoY); GAAP diluted EPS $12.41 (+46%); non-GAAP diluted EPS $11.56 (+13%).","Dupixent global net sales up 27% to $3.56B; EU approved for COPD; FDA decision expected Sept 27, 2024.","EYLEA HD/EYLEA U.S. sales $1.53B (+2%), including $304M from EYLEA HD.","Libtayo global net sales up 42% to $297M; pipeline progress in obesity, gene therapy, oncology.","New $3B share repurchase authorization; $601M repurchased in Q2; 2024 guidance updated."],"consensus_eps_estimate":null,"consensus_eps_actual":18.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":6692100000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216967,"accession_number":"0001104659-24-078172","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Regeneron expects $24M IPR&D charge in Q2 2024, ~$0.18 EPS hit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Estimated pre-tax acquired IPR&D charge of ~$24 million for Q2 2024.","Charge expected to negatively impact GAAP and non-GAAP EPS by ~$0.18 per diluted share.","Charge relates to up-front payments and equity premium on collaboration and licensing deals.","Results are preliminary and subject to financial close procedures; actual may vary."],"consensus_eps_estimate":null,"consensus_eps_actual":18.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":6692100000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236712,"accession_number":"0001104659-24-073372","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Regeneron shareholders elect directors, approve executive compensation at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class III directors elected: N.A. Coles, K. Guarini, A.F. Ryan, G.L. Sing; Class II director D.P. Schenkein elected.","Ratification of PwC as auditor for FY2024: 111.4M for, 5.3M against, 60.6K abstain.","Advisory vote on executive compensation passed: 106.7M for, 5.6M against, 207.5K abstain, 4.2M broker non-votes.","Non-binding shareholder proposal requesting simple majority voting approved: 85.9M for, 26.4M against, 188.7K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236711,"accession_number":"0001804220-24-000015","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q1 revenue down 1% to $3.15B; Non-GAAP EPS $9.55; new $3B buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $722M ($6.27 diluted EPS) vs $818M ($7.17) YoY; Non-GAAP net income $1,116M ($9.55).","Dupixent global net sales up 24% to $3.08B; EYLEA HD U.S. sales $200M, total EYLEA/HD $1.4B (down 2%).","Libtayo global net sales up 45% to $264M; Sanofi collaboration revenue up 14% to $910M.","Board authorized new $3.0B share repurchase; Q1 repurchases $298M, $1.2B remaining under prior program.","2024 guidance updated: GAAP R&D $4.92-5.17B, GAAP SG&A $2.94-3.09B; gross margin unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":6.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":3145000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254345,"accession_number":"0001804220-24-000006","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q4 revenues $3.43B (+1% YoY); Dupixent up 31%; full-year guidance issued","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP EPS $10.19, non-GAAP $11.86; FY GAAP EPS $34.77, non-GAAP $43.79.","Dupixent global net sales Q4 $3.22B (+31% YoY), FY $11.59B (+33%). EYLEA franchise U.S. net sales down 2% in Q4.","Pipeline: Dupixent COPD sBLA and linvoseltamab BLA submitted; EYLEA HD approved in EU/Japan.","FY2024 guidance: GAAP R&D $4.82-5.07B, SG&A $2.89-3.09B, gross margin 86-88%.","Share repurchases $2.215B in FY2023; $1.5B remain. CFO Robert Landry to retire."],"consensus_eps_estimate":null,"consensus_eps_actual":34.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":13117200000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254344,"accession_number":"0001104659-24-008807","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2024-01-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Regeneron appoints Christopher Fenimore as CFO to succeed retiring Robert Landry","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher Fenimore promoted to SVP, Finance and CFO; effective day after 2023 10-K filing (expected Feb 5, 2024).","Jason Pitofsky promoted to VP, Controller; no change in compensation.","Fenimore's base salary increased to $660,000; granted equity award with target fair value of $5,000,000.","Equity award includes options for 8,499 shares (4-year vest) and 2,370 RSUs (50% at years 2 and 4).","Succession plan previously disclosed; Landry retiring."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254343,"accession_number":"0001104659-24-002037","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Regeneron reports preliminary Q4 U.S. EYLEA HD sales of $123M; IPR&D charge of $30M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2023 U.S. net product sales: EYLEA HD $123M, EYLEA $1.34B, combined $1.46B.","Acquired IPR&D charge of $30M pre-tax from Intellia collaboration extension, reducing GAAP and non-GAAP EPS by ~$0.21.","Dupixent global net sales through 9M 2023: ~$8.4B, up 34% YoY; pivotal COPD data supports 2024 launch potential.","EYLEA HD FDA-approved August 2023 for wAMD, DME, DR; ~2/3 of eligible lives covered, permanent J-code expected April 1, 2024.","Oncology pipeline: BLAs submitted for odronextamab (B-NHL) and linvoseltamab (MM); potential for up to three FDA approvals by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":34.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":13117200000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271825,"accession_number":"0001804220-23-000029","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q3 revenue $3.36B (+15%); GAAP EPS $8.89, non-GAAP EPS $11.59; EYLEA HD launch begins","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.363B (+15% YoY); GAAP EPS $8.89, non-GAAP EPS $11.59.","EYLEA HD launched post-FDA approval, generated $43M U.S. net sales in Q3.","Dupixent global net sales (Sanofi) $3.10B (+33% YoY); Libtayo global net sales $232M (+62%).","FDA accepted priority reviews for odronextamab in FL/DLBCL and Dupixent in pediatric EoE; CRL for Dupixent in CSU.","CFO Robert Landry to retire Feb 2024; Christopher Fenimore to succeed."],"consensus_eps_estimate":null,"consensus_eps_actual":24.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":9682900000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271824,"accession_number":"0001104659-23-107161","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2023-10-05T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Regeneron expects $100M pre-tax IPR&D charge in Q3 2023 from Alnylam milestone","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Acquired IPR&D charge of $100M pre-tax due to clinical milestone for ALN-APP Alzheimer's program.","Charge expected to reduce GAAP and non-GAAP diluted EPS by approximately $0.78 in Q3 2023.","Milestone relates to collaboration with Alnylam Pharmaceuticals (ALNY) for early-onset Alzheimer's therapy.","Results for Q3 not finalized; actual amounts may differ from preliminary estimates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288670,"accession_number":"0001104659-23-099345","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2023-09-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Regeneron CFO Landry to retire Feb 2024; Fenimore named successor; two new directors elected","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Marc Tessier-Lavigne retired Sept 1, 2023 due to potential conflicts with other roles.","CFO Robert E. Landry to retire in Feb 2024; Christopher Fenimore (SVP, Controller) to succeed him.","Board elected Kathryn Guarini as Class III director and David Schenkein as Class II director effective Sept 8, 2023.","Both new directors appointed to Audit (Guarini) and Technology (Schenkein) committees.","No disagreements cited for Landry departure; new directors hold office until 2024 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288668,"accession_number":"0001104659-23-099351","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K/A","filed_at":"2023-09-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Regeneron board adopts annual say-on-pay vote frequency after shareholder approval","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders voted for every-one-year frequency at June 9, 2023 annual meeting.","Board on Sept 8, 2023 determined future advisory votes on exec compensation will be held annually.","Amendment filed solely to disclose the board's decision; no other changes to original report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288669,"accession_number":"0001804220-23-000021","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q2 revenues up 11% to $3.16B; EPS $8.50 GAAP/$10.24 non-GAAP","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2023 total revenues $3.158B (+11% YoY); GAAP diluted EPS $8.50 (up 14%); non-GAAP diluted EPS $10.24 (up 5%).","Dupixent global net sales (Sanofi) rose 33% to $2.79B; EYLEA US net sales fell 7% to $1.50B on lower pricing/competition.","FDA issued CRL for aflibercept 8 mg due to contract manufacturer issues; expects FDA action on BLA in Q3 2023.","Repurchased $723M in shares during Q2; $2.3B remained under buyback program as of June 30, 2023.","Updated 2023 guidance: GAAP R&D $4.315-4.455B; non-GAAP R&D $3.825-3.925B; SG&A and gross margin ranges unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":15.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":6320200000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309287,"accession_number":"0001104659-23-071187","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Regeneron shareholders re-elect all four Class II directors; bylaw amended to allow Co-Chairs","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Joseph Goldstein, Christine Poon, Craig Thompson, Huda Zoghbi elected as Class II directors at June 9 annual meeting.","Say-on-pay advisory vote approved (97.8M for, 14.5M against).","Shareholders selected one-year frequency for future say-on-pay votes (111.2M votes).","Non-binding proposal on access-to-medicine report rejected (10.6M for, 101.4M against).","Bylaw amended to permit Board to elect two Co-Chairs, either of whom can exercise full powers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309286,"accession_number":"0001804220-23-000015","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q1 revenue up 7% to $3.16B; GAAP EPS $7.17; non-GAAP $10.09","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total revenue $3.162B (+7% YoY); GAAP net income $818M (-16%); non-GAAP net income $1.168B (-11%).","EYLEA U.S. net sales $1.43B (-6% YoY); Dupixent global net sales $2.49B (+37%, recorded by Sanofi).","Aflibercept 8 mg BLA accepted for FDA priority review; target action date June 27, 2023 for wet AMD and DME.","Dupixent Phase 3 COPD trial met endpoints: 30% reduction in exacerbations; first biologic to show benefit in COPD.","Full-year 2023 guidance: GAAP R&D raised to $4.225-4.465B; GAAP SG&A raised to $2.49-2.68B; gross margin lowered to 87-89%."],"consensus_eps_estimate":null,"consensus_eps_actual":7.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":3162100000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309285,"accession_number":"0001104659-23-045897","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2023-04-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Regeneron Chair P. Roy Vagelos not to stand for re-election; Schleifer and Yancopoulos named Co-Chairs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Vagelos will not stand for re-election at June 9, 2023 Annual Meeting; will serve as Chair until then.","Board plans to elect Leonard S. Schleifer, M.D., Ph.D. and George D. Yancopoulos, M.D., Ph.D. as Co-Chairs.","Christine A. Poon will become Lead Independent Director effective after the Annual Meeting.","Dr. Vagelos's decision not due to any disagreement with Regeneron."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309284,"accession_number":"0001104659-23-043287","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2023-04-10T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Regeneron expects $56M IPR&D charge in Q1 2023 from Sonoma collaboration, ~$0.42 EPS impact","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pre-tax acquired IPR&D charge of ~$56M for Q1 2023 related to Sonoma Biotherapeutics collaboration.","Expected to reduce both GAAP and non-GAAP diluted EPS by approximately $0.42.","Charge is preliminary and subject to final financial statement closing procedures.","Relates to an up-front payment under the previously announced collaboration and license agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328030,"accession_number":"0001104659-23-038299","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2023-03-29T23:59:59+00:00","items":["2.03","1.01","9.01"],"status":"ready","headline":"Regeneron amends $720M lease financing to align covenants with Dec 2022 credit agreement","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Third A&R Participation Agreement aligns financial and operating covenants with credit agreement entered December 2022.","$720 million lease financing for corporate headquarters; maturity remains March 2027 with 5-year extension option.","Yield on advances unchanged, based on 1-month SOFR term rate plus spread and margin tied to debt rating/leverage.","No new borrowing; amendment and restatement of existing facility; lease term extended previously to 2027.","Regeneron guarantees obligations; subsidiary guarantors only join if they have borrowings under the credit agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328029,"accession_number":"0001804220-23-000005","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2023-02-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q4 revenue down 31% to $3.41B, core up 14%; GAAP EPS $10.50","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenues $3.41B (-31% YoY); ex-REGEN-COV/Ronapreve up 14% to $3.02B.","GAAP diluted EPS $10.50 (Q4) and $38.22 (FY); non-GAAP $12.56 (Q4) and $44.98 (FY).","EYLEA U.S. net sales $1.50B Q4 (-3%), FY $6.26B (+8%); Dupixent global net sales $2.45B Q4 (+38%), FY $8.68B (+40%).","Aflibercept 8 mg BLA submitted for wet AMD/DME in Dec 2022; FDA approved Libtayo+chemo for NSCLC; EC approved Dupixent for prurigo nodularis and EoE.","New $3.0B share repurchase program authorized Jan 2023; FY2023 guidance: non-GAAP R&D $3.725-3.925B, non-GAAP SG&A $2.130-2.280B."],"consensus_eps_estimate":null,"consensus_eps_actual":38.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":12172900000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328028,"accession_number":"0001104659-23-002091","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Regeneron: FY2022 EYLEA US sales $6.26B (+8%), Q4 $1.50B (-3%); expects $30M IPR&D charge","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FY2022 EYLEA US net product sales ~$6.26B (+8% YoY); Q4 2022 ~$1.50B (-3% YoY).","Q4 EYLEA negatively impacted by short-term shift to off-label compounded Avastin and temporary closure of co-pay assistance fund; reversal beginning per Dec 2022 market data.","Expects ~$30M IPR&D charge from CytomX collaboration, reducing Q4 2022 GAAP/non-GAAP diluted EPS by ~$0.21.","Aflibercept 8 mg BLA submitted for wAMD and DME using priority review voucher; potential FDA approval by late August 2023.","Dupixent approved in 2022 for AD infants (6mo-5yr), EoE, prurigo nodularis; sBLA submitted for CSU in biologic-naïve patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345690,"accession_number":"0001104659-22-128613","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2022-12-20T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Regeneron enters into new $750M revolving credit facility, replaces prior facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $750M senior unsecured five-year revolving credit facility maturing Dec 19, 2027.","Interest rate variable: SOFR or alternate base rate plus margin tied to debt rating and leverage ratio.","Includes $500M accordion to increase commitments or add term loans with lender consent.","ESG amendment option to adjust pricing based on environmental, social, governance targets.","No borrowings outstanding at closing; prior $750M facility terminated simultaneously."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345689,"accession_number":"0001804220-22-000029","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q3 revenues down 15% to $2.94B; ex-REGEN-COV up 11%; EPS $11.66","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $11.66 (Q3 2021: $14.33); non-GAAP $11.14 ($15.37).","EYLEA U.S. net sales record $1.63B (+11% YoY); Dupixent global sales $2.33B (+40%).","Aflibercept 8 mg met primary endpoints in DME and wet AMD pivotal trials; BLA submission planned late 2022.","FDA granted EYLEA pediatric exclusivity through May 17, 2024; share repurchases $913M in Q3.","Full-year 2022 GAAP R&D guidance raised to $3.515-$3.600B; SG&A to $2.010-$2.090B."],"consensus_eps_estimate":null,"consensus_eps_actual":27.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":8758500000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345688,"accession_number":"0001104659-22-104901","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2022-10-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Regeneron elects Craig B. Thompson, M.D. as director; board expands to 13 members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Craig B. Thompson elected as director effective October 3, 2022; board expands from 12 to 13.","Appointed to Technology Committee; term runs until 2023 Annual Shareholder Meeting.","Compensation follows standard non-employee director practices described in April 21, 2022 proxy.","No arrangement or understanding with any other person regarding his selection as director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362111,"accession_number":"0001804220-22-000020","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q2 revenue down 44% to $2.86B; core revenue up 20%; EPS $7.47 GAAP, $9.77 non-GAAP","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Excluding REGEN-COV, total revenue grew 20% to $2.849B, driven by EYLEA ($1.62B +14%) and Dupixent ($2.09B +40%).","GAAP net income $852M ($7.47 diluted EPS) vs $3.099B ($27.97) Q2 2021; non-GAAP EPS $9.77 vs $25.80.","Acquired Checkmate Pharmaceuticals for ~$250M and purchased Sanofi's Libtayo worldwide rights for $900M up-front.","FDA approved Dupixent for atopic dermatitis in children 6 months-5 years and eosinophilic esophagitis; priority review for prurigo nodularis.","Updated 2022 guidance: R&D $3.485-3.655B GAAP; SG&A $1.99-2.11B; gross margin on net product sales 90-91%."],"consensus_eps_estimate":null,"consensus_eps_actual":16.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":5822300000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381617,"accession_number":"0001104659-22-071446","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2022-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Regeneron shareholders re-elect four Class I directors, approve auditor, advisory pay vote at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board nominees Bassler, Brown, Schleifer, Yancopoulos re-elected with 96.9M, 86.3M, 110.1M, 109.5M votes for, respectively.","Ratification of PwC as independent auditor for FY2022 approved: 111.8M for, 4.5M against.","Advisory vote on named executive officer compensation approved: 97.8M for, 13.6M against, 4.7M broker non-votes.","All three proposals passed; no contested items or shareholder proposals on ballot."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381616,"accession_number":"0001104659-22-067375","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2022-06-02T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Regeneron enters amended deal with Sanofi for full rights to Libtayo; pays $900M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Regeneron gains sole worldwide rights to develop and commercialize Libtayo, effective upon regulatory approvals.","Regeneron will pay Sanofi $900M upfront within 10 business days of effective date.","Regeneron will pay an 11% royalty on Libtayo net sales through March 2034, plus up to $200M in milestone payments.","Development cost reimbursement rate under Antibody LCA increased from 10% to 20% effective April 1, 2022.","Transition services, distribution, and manufacturing agreements support the handover from Sanofi."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381615,"accession_number":"0001804220-22-000013","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q1 revenue up 17% to $2.97B; non-GAAP EPS $11.49, GAAP EPS $8.61; Dupixent +43%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $2.97B (+17% YoY); ex-REGEN-COV revenue +25%; GAAP net income $974M, diluted EPS $8.61.","Non-GAAP net income $1.32B, diluted EPS $11.49 (+16% YoY); free cash flow $1.96B.","EYLEA U.S. net sales $1.52B (+13%); Dupixent global net sales $1.81B (+43% as recorded by Sanofi).","R&D guidance raised to $3.27-$3.50B (GAAP), $2.90-$3.10B (non-GAAP); SG&A guidance unchanged.","REGEN-COV inventory write-offs $58M in COGS; $211M unrealized losses on equity securities; EUA revised."],"consensus_eps_estimate":null,"consensus_eps_actual":8.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":2965100000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399614,"accession_number":"0001104659-22-031232","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2022-03-08T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Regeneron extends $720M lease financing for headquarters by five years to 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Five-year extension of $720M lease financing originally from 2017; new maturity March 3, 2027.","Yield on advances changed to one-month SOFR plus spread adjustment and margin tied to debt rating/leverage.","Lessee may extend another five years with all Participants' consent; prepayment allowed without premium.","Guarantors: Regeneron, Regeneron Healthcare Solutions, and Regeneron Genetics Center (joint and several).","Covenants mirror existing credit agreement: max total leverage ratio, min interest expense coverage, restricted payments test."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399613,"accession_number":"0001804220-22-000004","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2022-02-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q4 revenue surges 104% to $4.95B; REGEN-COV writedown $232M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP diluted EPS $19.69 vs $10.24; non-GAAP EPS $23.72 vs $9.53.","EYLEA U.S. net sales $1.55B (+15% YoY); full year $5.79B (+17%).","$232M writedown of REGEN-COV inventory due to Omicron; EUA revised to exclude Omicron regions.","FY2022 non-GAAP guidance: R&D $2.8B-$3.0B; SG&A $1.65B-$1.77B; gross margin 90-92%.","Board authorized $3B share repurchase program."],"consensus_eps_estimate":null,"consensus_eps_actual":71.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":16071700000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399612,"accession_number":"0001104659-22-002403","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Regeneron reports preliminary FY2021 U.S. EYLEA sales of $5.79B, REGEN-COV sales of $5.82B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["EYLEA FY2021 U.S. net product sales ~$5.79B (+17% YoY); Q4 sales ~$1.54B (+15% YoY).","REGEN-COV FY2021 U.S. net product sales ~$5.82B; Q4 sales ~$2.29B.","Provided corporate update at J.P. Morgan conference; highlighted pipeline progress including Aflibercept 8mg Ph3 data expected 2H22.","Dupixent annualizing at ~$6.6B run rate; three potential new Ph3 indications in 2022 (CSU, PN, EoE).","Announced $3B share repurchase program in Nov 2021; over $7.5B repurchased since Nov 2019."],"consensus_eps_estimate":null,"consensus_eps_actual":71.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":16071700000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418597,"accession_number":"0001804220-21-000031","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q3 revenues $3.45B (+51% YoY); GAAP EPS $14.33, non-GAAP $15.37","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $3.45B, up 51% YoY; GAAP net income $1.63B ($14.33 diluted EPS); non-GAAP net income $1.77B ($15.37 diluted EPS).","EYLEA U.S. net sales $1.47B (+12% YoY); Dupixent global net sales (Sanofi) $1.66B (+55% YoY).","REGEN-COV contributed $804M (U.S. product sales $677M + Roche profit share); new U.S. government supply agreement for 1.4M doses.","Pipeline: FDA expanded Dupixent to children 6-11 with asthma; positive Phase 3 data in CSU, EoE, prurigo nodularis; REGEN-COV BLA accepted for priority review.","FY 2021 guidance updated: R&D lowered to $2.845-2.915B GAAP; SG&A narrowed to $1.76-1.83B; gross margin ~87.5% GAAP; capex reduced."],"consensus_eps_estimate":null,"consensus_eps_actual":52.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":11120000000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436152,"accession_number":"0001104659-21-116352","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2021-09-16T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Regeneron to supply 1.4M additional REGEN-COV doses to U.S. Government for $2.94B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment obligates U.S. Government to buy 1.4 million doses at $2,100 each, totaling $2.94 billion.","Regeneron must deliver at least 100,000 doses per month (Sept–Dec 2021); all by January 31, 2022.","Doses are for use under FDA Emergency Use Authorization for certain individuals in the U.S.","Agreement includes government's right to terminate for convenience; Regeneron gets termination costs based on work performed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436151,"accession_number":"0001804220-21-000023","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2021-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q2 revenue up 163% to $5.14B; GAAP EPS $27.97; EYLEA sales record $1.42B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $5.14B (+163% YoY) including $2.59B REGEN-COV; core revenue ex-REGEN-COV +22%.","GAAP diluted EPS $27.97 vs $7.61 in Q2 2020; non-GAAP diluted EPS $25.80 vs $7.16.","EYLEA US net sales record $1.42B (+28% YoY); Dupixent global net sales $1.50B (+59% YoY, recorded by Sanofi).","REGEN-COV: $2.59B US sales from 1.25M doses; EUA expanded for prophylaxis; Japan full approval; RECOVERY trial showed 20% mortality reduction in seronegative.","Pipeline: Dupixent Phase 3 CSU positive; Libtayo Phase 3 NSCLC stopped early for survival benefit; $1.8B Tarrytown campus expansion over 6 years."],"consensus_eps_estimate":null,"consensus_eps_actual":38.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":7667200000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}